Brom Rector
Brom Rector and XEIA
All episodes
Best episodes
Seasons
Top 10 Brom Rector Episodes
Goodpods has curated a list of the 10 best Brom Rector episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Brom Rector for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Brom Rector episode by adding your comments to the episode page.
04/30/24 • 60 min
Can a succulent plant from South Africa treat premature ejaculation? John Boghossian and Dr Ryan Protzko from Kadence Bio think so.
Dillan DiNardo - CEO of Mindstate Design Labs | Creating Novel Psychoactive Drugs at Y Combinator
Brom Rector
02/10/22 • 41 min
Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.
Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders. Mindstate participated in Y Combinator in 2021.
Check out Mindstate @ https://www.mindstate.design/
05/15/25 • 117 min
Brom Rector and Sam Tabone from XEIA get specific on what Human 3 actually looks like in practice by analyzing 10 startups through the Human 3 lens.
We analyze the companies on the 5 pillars of Human 3
- Distribution shifting potential - can this company elevate the already healthy in addition to healing the sick?
- HERO - is the company inspired by Historical Examples of Real-world Outcomes
- Step Change potential - if this thing works, will it be an order of magnitude better than the standard of care?
- Endogenous Accelerant - does the company have a built in flywheel?
- X-disciplinarity - does the innovation happen at the intersection of multiple disciplines?
Timestamps and companies mentioned:
0:00 - what defines a Human 3 startup?
16:00 - Mindstate Design Labs: AI designed psychedelic therapies
25:00 - Kadence Bio: treatment for premature ejaculation
34:20 - NeuroBionics: minimally invasive deep brain stimulation for Parkinson's
42:00 - Motif Neurotech: minimally invasive TMS for depression
51:45 - Xylo Bio: non-hallucinogenic psychedelics
1:01:45 - Pangea Bio: AI to identify natures hidden cures
1:11:00 - Kerna Labs: AI model to unlock the therapeutic potential of mRNA
1:20:00 - Superpower: concierge longevity medicine on your iPhone
1:30:00 - Coherence: closed loop neuromodulation to treat brain cancer (Glioblastoma)
1:40:27 - Beond: treating Opiate addiction with Ibogaine
1:52:00 - closing thoughts
Cybin CEO Doug Drysdale: Sublingual Psilocybin, Next-Gen Psychedelics & Brain Imaging Technology
Brom Rector
06/06/21 • 61 min
Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology. In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:
- Why is Cybin's sublingual psilocybin potentially superior to offerings from Compass Pathways and Usona?
- How might deuterated tryptamines provide a superior psychedelic experience compared to classic psychedelics like psilocybin and LSD?
- Why is Cybin's partnership with brain imaging company Kernel so powerful?
- and the ultimate question for investors: is Cybin undervalued?
👇👇👇 Links 👇👇👇
📺 Watch on YouTube: https://youtu.be/cAsFHlVLpeA
💻 The Integration Co Website: https:/theintegration.co
📝 My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms: https://anchor.fm/theintegrationco
🐦 brom on twitter: https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram: https://instagram.com/theintegrationco
💌 Email: [email protected]
⏰ Timestamps:
- 0:00 - intro / disclaimer / disclosures
- 4:20 - Cybin overview / Doug background
- 8:50 - What are the differences between traditional pharma & psychedelic pharma?
- 11:30 - How will Cybin deliver its drugs? Clinics?
- 13:00 - Cybin's sublingual psilocybin
- 15:45 - Is sublingual psilocybin as effective as normal psilocybin?
- 17:00 - More on Cybin and clinics
- 18:30 - is psychedelic decriminalization a threat to psychedelic pharma?
- 20:30 - Doug Drysdale on Compass Pathway's patents
- 22:00 - Cybin's Deuterated Tryptamines
- 24:30 - How does Cybin choose which drug will work for a given indication?
- 27:30 - What makes deuterated tryptamines different?
- 29:30 - Is reducing the hallucinogenic effect of psychedelics desirable?
- 32:00 - Cybin's inhalation and ODT delivery methods?
- 33:33 - Cybin's partnership with Kernel
- 40:00 - What are Cybin's upcoming catalysts?
- 42:00 - Is Cybin undervalued?
- 44:45 - Why is most psychedelic research being done by small startup companies?
- 47:00 - Is the psychedelic space overcrowded?
- 50:00 - Post-Interview analysis
Tom Feegel, CEO of Beond - Ending the Opiate Addiction Epidemic with Safe Ibogaine Treatment
Brom Rector
03/27/22 • 58 min
Tom Feegel is the Founder and CEO of Beond. Beond exists to help end the opiate addiction epidemic with safe ibogaine treatment.
In this episode Tom speaks on the severity of the opioid epidemic and explains how ibogaine assisted therapy can help heal those who are suffering from addiction. Tom gets into his personal story, how Ibogaine helped someone in his family, the economics of addiction treatment and Beond's plans to scale into a global operation.
How Life Science VCs do Due Diligence on Potential Investments - Sam Tabone, Focalpoint Partners
Brom Rector
10/04/22 • 118 min
Today’s guest is Samantha Tabone. Sam is a Partner at Focalpoint where she leads in-depth technical and scientific due diligence on Empath’s psychedelic biotech investments. Sam is here to help break down the due diligence process Empath uses when evaluating potential investments in psychedelic biotech companies. Empath's Due Diligence process is broken down into 4 pillars: Team, Intellectual Property, Scientific Foundations and Operations / Strategy.
Prior to Focalpoint, Sam served as the VP of R&D for PurMinds, a neuromedicine startup developing novel therapeutics for neurodegenerative diseases. As an independent consultant she’s led projects for leading psychedelic companies including Beckley Psytech, advised family offices on Life Science investment strategies, and worked as a temporary strategic director at several biotech startups. Sam has been fascinated with neuroscience and psychedelics (especially DMT) since she was in her teens. She’s most excited about funding psychedelic startups working towards solutions for complex neurological disorders. She holds a B.S. in Chemistry from the University of Toronto and attended the University of Wisconsin-Madison’s Pharmaceutical Sciences Master’s program.
06/30/22 • 61 min
Sam Banister is a medicinal chemist and co-founder of Psylo. Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness.
Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made, and how new chemical entities are going to play a dominant role in the future of psychedelic medicine.
Make sure to subscribe to the show!
Follow Brom on twitter: https://twitter.com/therealbrom
Follow Sam on twitter: https://twitter.com/samuel_b_phd
Brom's VC Fund: https://www.empath.vc
Highlighted Timestamps:
06:12 - Are next generation psychedelics taking over in 10 years?
16:10 - What is the process like for creating a new chemical entities?
50:39 - Psychedelics vs Cannabis: New drug discoveries
06/27/21 • 36 min
What exactly is psychedelic therapy, and what does the research on psychedelic therapy tell us about its effectiveness?
In this episode of The Integration Conversation, Brom provides a description of what exactly happens during psychedelic therapy, and then goes over the three most compelling clinical research papers on psychedelic therapy.
Learn about how MDMA can treat Post Traumatic Stress Disorder, psilocybin can treat depression, and how psilocybin stacks up against SSRIs like Lexapro.
👇 studies mentioned in this video
MDMA for PTSD https://www.nature.com/articles/s41591-021-01336-3
Trial of Psilocybin versus Escitalopram for Depression
https://www.nejm.org/doi/full/10.1056/NEJMoa2032994
Psilocybin to treat Depression and Anxiety in Cancer patients
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/
Psilocybin for smoking Cessation
https://files.csp.org/Psilocybin/Johnson2017Smoking.pdf
Ibogaine for Opioid Dependence
https://pubmed.ncbi.nlm.nih.gov/28402682/
Investing in Psychedelic Medicine FAQ
Brom Rector
06/20/21 • 38 min
In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.
Topics Include:
- What does "investing in psychedelics" actually mean?
- How big could the psychedelics market get?
- What problems are psychedelics solving?
- What are the different sub-segments of the psychedelic industry
- Why is now the right time to get involved in the psychedelics industry?
- Won't decriminalization destroy profits?
- Aren't psychedelics just cannabis 2.0?
⏰ Timestamps:
- 0:00 - intro
- 5:00 - What exactly is "investing in psychedelics"?
- 8:00 - How is mental health currently treated?
- 10:00 - Mental health is trending in the wrong direction.
- 13:00 - How are psychedelics different?
- 13:45 - What types of businesses exist in the psychedelics industry?
- 20:00 - How to evaluate a psychedelic business?
- 22:30 - What business models should be avoided?
- 24:30 - Why is now the right time to invest in psychedelics?
- 27:30 - Is psychedelics just cannabis 2.0?
- 31:30 - Won't decriminalization destroy profits?
07/08/24 • 60 min
Lars Wilde is the cofounder of Pangea Bio - startup that uses AI to identify natural compounds and traditional remedies that may have medical applications. Prior to starting Pangea, Lars cofounded Compass Pathways and ATAI life sciences, both of which IPOd on the NASDAQ.
Show more best episodes
Show more best episodes
FAQ
How many episodes does Brom Rector have?
Brom Rector currently has 22 episodes available.
What topics does Brom Rector cover?
The podcast is about Podcasts and Technology.
What is the most popular episode on Brom Rector?
The episode title 'Advancements in Male Sexual Health w/ John Boghossian & Ryan Protzko of Kadence Bio' is the most popular.
What is the average episode length on Brom Rector?
The average episode length on Brom Rector is 65 minutes.
How often are episodes of Brom Rector released?
Episodes of Brom Rector are typically released every 49 days, 23 hours.
When was the first episode of Brom Rector?
The first episode of Brom Rector was released on Jun 6, 2021.
Show more FAQ
Show more FAQ